For more information or confidential assistance
800-306-3180
se habla español

Ava Lawson

Ava has served as writer and contributing editor with Drug Reporter since 2013. Breaking news on pharmaceutical and medical device litigation, consumer safety and medical research are her primary writing specialties.

Androgel Bellwether Trial Ruling Favors Plaintiffs

Premises liability lawyer Los Angeles
In a case management order filed by US District Judge Matthew F. Kennelly, Androgel maker AbbVie was denied its attempt to have the first bellwether case dismissed on grounds that the statute of limitations had expired. The testosterone lawsuit, filed by Jeffrey Konrad, was originally selected as a representative case... Read more »

New Study Highlights Nexium Dangers

Recent large scale epidemiological and retrospective studies have demonstrated links between the use of proton pump inhibitors (PPIs) and an increased risk of renal failure, myocardial infarction and dementia. On top of this, medical experts say that up to 70 percent of patients that take PPIs for treatment of heartburn... Read more »

Fresenius Announces $250 Million Granuflo Settlement

Fresenius Medical Care North America agreed to a $250 million settlement to resolve lawsuits that claim the company was aware of risks of their dialysis products yet failed to warn the public. The litigation centers upon Granuflo and Naturalyte, two dialysates that have been blamed for heart problems, strokes and death... Read more »

Oregon Mother Claims Zofran Caused Baby’s Cleft Palate

pregnant woman wearing white in profile
An increasing number of lawsuits involving Zofran-related birth defects have been filed across the nation. One of the latest claims was brought by an Oregon mother who argues that her child’s cleft palate and laryngeal cleft are a direct result of the anti-nausea drug she took while pregnant. GlaxoSmithKline LLC... Read more »

Plaintiff Argues Zofran Caused Son’s Heart Defect

pregnant woman wearing white in profile
A recent complaint was filed in the United States District Court for the District of Massachusetts, where it joins the Zofran (Ondansetron) Products Liability Litigation known as MDL 2657. The case centers upon allegations that drug maker GlaxoSmithKline (GSK) negligently marketed its powerful anti-nausea drug to pregnant women without providing... Read more »

Plaintiff Blames Invokana for Severe Kidney Damage

Plaintiff Gene Schurman, a resident of Illinois, claims he suffered severe kidney damage after taking the diabetes drug Invokana under the direction of his doctor. He is now suing Janssen Pharmaceuticals, Johnson & Johnson and Mitsubishi Tanabe Pharma Corporation on claims of failure to warn, product liability, design defect, fraud,... Read more »

Androgel Lawsuits Identified for Bellwether Trial Pool

The first bellwether trials in multidistrict litigation 2545, which concerns injuries allegedly caused by testosterone replacement therapy, are slated to go to trial by fall of 2016. Court dockets show that more than 2,700 complaints are currently pending against the manufacturers of Testim, Adroderm, Androgel, Axiron and other products that... Read more »

Report Highlights Diabetic Ketoacidosis Risk Factors for SGLT2 Inhibitor Patients

Earlier this year, the U.S. Food and Drug Administration (FDA) published a safety communication that alerts consumers about an increased risk of diabetic ketoacidosis (DKA) with the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors, including Invokana, Invokamet, Farxiga, Jardiance and others. Diabetic ketoacidosis is a potentially life-threatening complication of diabetes... Read more »

Testosterone Injury Lawsuits Approach 2,000 Mark

The number of product liability complaints regarding testosterone replacement therapy continues to skyrocket, with allegations that the products caused heart attacks, stroke, and debilitating blood clot injuries. Men who took supplements such as Axiron, Testim and Androgel are seeking fair compensation and justice through the legal system, based on counts... Read more »